“Play the field right and there’s money to be made even off some of the shit companies purely based on the wave.”

Many predicted an ethical storm brewing in the lead-up to the explosion of for-profit interest in psychedelic pharmaceuticals. But, were their efforts to mitigate the damage enough to make a difference?

"I want nothing to do with those kinds of folks who want to decriminalize psychedelics,” Rahn told Forbes."

This list is by no means exhaustive, but it spotlights a number of psychedelic pharmaceutical companies and executives with ties to extractive industry.

DoubleBlind claims its recently-unveiled New York City billboard is a lot of things, except what it actually is: a giant advertisement.

The Psymposia team discusses the reticence of psychedelic advocates to consider cases of unequivocal abuse and neglect of participants in MAPS clinical trials. We provide background on the gap between the public image of MAPS and the experiences shared by Meaghan, Mel, and Leah in New York Magazine's Cover Story Season 1, Power Trip.

Last Week Tonight joined a long and growing list of media outlets that have added fuel to the hype of psychedelic medicalization. By omitting the potential risks and actual harms associated with psychedelic-assisted therapy, this messaging increases the risk to the public by presenting unrealistic expectations about experimental treatments.

This is the first article in a series investigating the Church of Psilomethoxin (CoP), exploring the recent debate about the Church's sacrament and the people involved in promoting the Church and its claims.

What is neurogenesis? Do psychedelics really cause it? If they do, what doors might that open up?

As the coronavirus pandemic rages on, Christian Angermayer, the world’s largest psychedelic pharmaceutical investor and founder of ATAI Life Sciences, calls to sacrifice public health for the sake of “the economy.”